Sinovac Biotech (NASDAQ:SVA) received product license from China National Medical Products Administration for its quadrivalent influenza vaccine which would be available to China market for the 2020-2021 influenza season protecting a target group of 3 years or older.
Sinovac’s licensed influenza vaccine portfolio consists of three more vaccines thereby enabling the company to provide variety of solutions again.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.